Dashboard
1
Poor Management Efficiency with a low ROCE of 36.27%
- The company has been able to generate a Return on Capital Employed (avg) of 36.27% signifying low profitability per unit of total capital (equity and debt)
2
The company is Net-Debt Free
3
Poor long term growth as Net Sales has grown by an annual rate of -17.97% and Operating profit at -39.75% over the last 5 years
4
Flat results in Jun 26
5
With ROE of 4.62%, it has a expensive valuation with a 4.02 Price to Book Value
Stock DNA
Pharmaceuticals & Biotechnology
CNY 22,761 Million (Large Cap)
87.00
NA
0.35%
0.03
4.62%
3.98
Revenue and Profits:
Net Sales:
1,224 Million
(Quarterly Results - Jun 2026)
Net Profit:
93 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-7.48%
0%
-7.48%
6 Months
-13.75%
0%
-13.75%
1 Year
94.58%
0%
94.58%
2 Years
301.56%
0%
301.56%
3 Years
195.82%
0%
195.82%
4 Years
103.02%
0%
103.02%
5 Years
150.91%
0%
150.91%
Zhende Medical Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
-17.97%
EBIT Growth (5y)
-39.75%
EBIT to Interest (avg)
12.92
Debt to EBITDA (avg)
Net Debt is too low
Net Debt to Equity (avg)
-0.02
Sales to Capital Employed (avg)
0.62
Tax Ratio
17.14%
Dividend Payout Ratio
30.42%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
8.81%
ROE (avg)
21.96%
Valuation key factors
Factor
Value
P/E Ratio
87
Industry P/E
Price to Book Value
4.02
EV to EBIT
76.24
EV to EBITDA
43.64
EV to Capital Employed
3.91
EV to Sales
5.35
PEG Ratio
NA
Dividend Yield
0.35%
ROCE (Latest)
5.13%
ROE (Latest)
4.62%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Bearish
Bullish
Dow Theory
Mildly Bullish
Mildly Bearish
OBV
No Trend
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'26 - QoQ
Jun'26
Mar'26
Change(%)
Net Sales
1,223.60
1,000.40
22.31%
Operating Profit (PBDIT) excl Other Income
186.50
145.60
28.09%
Interest
7.60
8.10
-6.17%
Exceptional Items
-0.80
11.50
-106.96%
Consolidate Net Profit
93.50
57.60
62.33%
Operating Profit Margin (Excl OI)
82.90%
60.50%
2.24%
USD in Million.
Net Sales
QoQ Growth in quarter ended Jun 2026 is 22.31% vs -12.65% in Mar 2026
Consolidated Net Profit
QoQ Growth in quarter ended Jun 2026 is 62.33% vs 1.77% in Mar 2026
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
4,306.30
4,247.90
1.37%
Operating Profit (PBDIT) excl Other Income
603.90
602.60
0.22%
Interest
35.60
31.60
12.66%
Exceptional Items
3.10
-21.10
114.69%
Consolidate Net Profit
267.10
397.20
-32.75%
Operating Profit Margin (Excl OI)
70.90%
83.50%
-1.26%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 1.37% vs 3.27% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is -32.75% vs 86.13% in Dec 2024
About Zhende Medical Co., Ltd. 
Zhende Medical Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available
Footer loading






